Seagen Inc
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
321 / 1361
Position in country
5722 / 14179
Return on Assets, %
-21
-40.3
Net income margin, %
-33.3
-180
EBITDA margin, %
-32.3
-168.2
Debt to Equity, %
0
3.2
Intangible assets and goodwill, %
13.6
0.2
Revenue CAGR 3Y, %
28.8
12.5
Total Equity change 1Y, %
-9.1
-9
Revenue Y, % chg
17.2
0
P/BV
18.6
1.8
EV/EBITDA
-40.8
-1.6
Competitors
Ranks
-
Vertex Pharmaceuticals Inc
00%
-
Regeneron Pharmaceuticals Inc
00%
-
Gilead Sciences Inc
00%
-
Biomarin Pharmaceutical Inc
00%
-
Seagen Inc
00%
-
Amgen Inc
00%
-
Moderna Inc
00%
-
Alnylam Pharmaceuticals Inc
00%
-
AbbVie Inc
00%
-
Biogen Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
United States of America
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Sub-sector
Health Care
Capitalization (millions of $)
43154.6
Ticker
SGEN.O
ISIN
US81181C1045
IPO date
Availability on Russian exchanges
Yes
Reporting for
2023-11-01
Date fact. publication of reports
2023-09-30
Company Description
Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in the development and sale of pharmaceutical products on its own, behalf or in collaboration with others. The Company is commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. The Company also develops a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs. Its programs, including ADCETRIS and PADCEV, are based on its antibody-drug conjugate (ADC), technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The Company's approved medicines include ADCETRIS, PADCEV and TUKYSA.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: